An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
<p>WASHINGTON — An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about the safety of the&#
</p><p>An outside panel of FDA advisers will consider the staff's view during a meeting on Monday in which they will vote on whether the drug's benefits outweigh its risks, according&a
Traffic Weather Sports Classifieds Cars Jobs Homes Television Radio Salt Lake Utah Local
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Alphabet names Eli Lilly veteran Ashkenazi as CFOAlphabet names Eli Lilly veteran Ashkenazi as CFO
Read more »
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFOThe new Google executive will replace Ruth Porat, who will become president and chief investment officer of the company after nearly a decade as CFO.
Read more »
Eli Lilly's diabetes drug tirzepatide gets approval in ChinaEli Lilly's diabetes drug tirzepatide gets approval in China
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulinsThe rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulinsThe rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Read more »
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supplyDemand for the drugs Mounjaro and Zepbound has far outpaced supply over the last year, forcing Eli Lilly to invest heavily to scale up its manufacturing.
Read more »